Wells Fargo Downgrades OncoMed Pharmaceuticals (OMED) to Market Perform Following Acquisition Offer
Tweet
Share
E-mailGet Alerts OMED Hot Sheet
Price: $0.89 --0%
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Rating Summary:
1 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 18 | Down: 16 | New: 9
Join SI Premium – FREE
Wells Fargo analyst Jim Birchenough downgraded OncoMed Pharmaceuticals (NASDAQ: OMED) from Outperform to Market Perform with a price target of $1.50 (from $8.00).
For an analyst ratings summary and ratings history on OncoMed Pharmaceuticals click here. For more ratings news on OncoMed Pharmaceuticals click here.
Shares of OncoMed Pharmaceuticals closed at $1.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Denso Corp. (6902:JP) (DNZOY) to Underweight
- JPMorgan Upgrades KCE Electronics PCL (KCE:TB) to Overweight
- Hon Hai Precision Industry Co Ltd. (2317:TT) (HNHPD) PT Raised to NT$435 at Macquarie
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
